Skip to main content
. Author manuscript; available in PMC: 2017 Jul 17.
Published in final edited form as: Cell. 2016 Dec 1;167(6):1525–1539.e17. doi: 10.1016/j.cell.2016.11.005

Figure 6. LATS1/2-Deleted Tumor EVs Stimulate Anti-tumor Immunity via the TLRs-Type I IFN Pathway.

Figure 6

(A–G) WT or LATS1/2 dKO B16-OVA cells were transplanted into mice deficient in Myd88 (A; n = 12 mice for the WT group, and n = 13 mice for the LATS1/2 dKO group), Ticam1 (also known as TRIF) (B; n = 6 mice for each group), Tmem173 (also known as STING) (C; n = 4 mice for each group), Casp1 (also known as caspase-1) (D; n = 4 mice for the WT group, and n = 5 mice for the LATS1/2 dKO group), Tlr4 (E; n = 9 mice for each group), Tlr7 (F; n = 8 mice for each group), or Tlr9 (G; n = 7 mice for each group), and Kaplan-Meier tumor-free survival curves are shown. The survival curves of WT C57BL/6 mice injected with WT or LATS1/2 dKO B16-OVA in Figure 2C are shown in a lighter color for reference. The p value was determined using a log-rank test, comparing KO mice injected with LATS1/2 dKO B16-OVA cells (orange) to corresponding wild-type C57BL/6 mice injected with LATS1/2 dKO B16-OVA cells (light red). ns, not significant (p > 0.05); *p < 0.05; **p < 0.01; ***p < 0.001.

(H) WT or LATS1/2 dKO B16-OVA cells were injected into Ifnar1 KO mice that lack functional type I IFN receptor, and tumor growth was monitored after the indicated times. The tumor growth curves of WT or LATS1/2 dKO B16-OVA cells injected into wild-type C57BL/6 mice in Figure 2A are shown in a lighter color for reference. Data are presented as means ± SEM; n = 8 tumors for each group.

(I) Kaplan-Meier tumor-free survival curves for mice injected as in (H) are shown (n = 8 mice for each group). The survival curves of WT C57BL/6 mice injected with WT or LATS1/2 dKO B16-OVA in Figure 2C are shown in a lighter color for reference. The p value was determined using a log-rank test, comparing Ifnar1 KO mice injected with LATS1/2 dKO B16-OVA cells (orange) to corresponding WT C57BL/6 mice injected with LATS1/2 dKO B16-OVA cells (light red). ***p < 0.001. See also Figure S7.